Klaria Year-End Report
Klaria Year-End Report 1 January–31 December 2022 Q4 2022Summary of the Year-End Report Successful rights issue brought 59.2 MSEK to Klaria New collaboration agreement signed with PharmaMar fourth quarter of 2022 - Net sales amounted to 2.2 MSEK (0.0 MSEK) - Other income amounted to 0.2 MSEK (6.2 MSEK) - R&D costs for the period amounted to 8.6 MSEK (28.1 MSEK) - Profit after tax amounted to -12.9 MSEK (-24.8 MSEK) - Earnings per share for the quarter amounted to -0.22 SEK (-0.48 SEK) - Cash flow from operating activities amounted to -10.7 MSEK (-14.6 MSEK) - Cash